UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Journal of thoracic oncology, 2018-05, Vol.13 (5), p.682-688

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Science (American Association for the Advancement of Science), 2015-04, Vol.348 (6230), p.124-128

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

American journal of respiratory and critical care medicine, 2019-09, Vol.200 (6), p.e31-e43

2019

Link zum Volltext

Verfügbarkeit prüfen

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2018-07, Vol.6 (1), p.75-75, Article 75

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Frontiers in oncology, 2023-09, Vol.13, p.1247879-1247879

2023

Link zum Volltext

Verfügbarkeit prüfen

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Frontiers in immunology, 2020-06, Vol.11, p.1036-1036

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

The New England journal of medicine, 2017-06, Vol.376 (25), p.2483-2485

Garon, Edward B

2017

Link zum Volltext

Verfügbarkeit prüfen

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer

JTO clinical and research reports, 2020-03, Vol.1 (1), p.100001-100001, Article 100001

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

Frontiers in oncology, 2020-10, Vol.10, p.572895-572895

2020

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Clinical cancer research, 2021-02, Vol.27 (4), p.905-907

Garon, Edward B

2021

Link zum Volltext

Verfügbarkeit prüfen

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Cancer medicine (Malden, MA), 2022-01, Vol.11 (2), p.530-538

2022

Link zum Volltext

Verfügbarkeit prüfen

The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role

Cancer biology & medicine, 2017-11, Vol.14 (4), p.341-347

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100205-100205, Article 100205

2021

Link zum Volltext

Verfügbarkeit prüfen

Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary

Clinical advances in hematology & oncology, 2023-10, Vol.21 Suppl 5 (10), p.13-16

Garon, Edward B

2023

Link zum Volltext

Verfügbarkeit prüfen

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.890-900

2013

Link zum Volltext

Verfügbarkeit prüfen

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.205-215

2021

Link zum Volltext

Verfügbarkeit prüfen

High efficiency vortex trapping of circulating tumor cells

Biomicrofluidics, 2015-11, Vol.9 (6), p.064116-064116

2015

Link zum Volltext

Verfügbarkeit prüfen

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC

Molecular cancer research, 2014-05, Vol.12 (5), p.765-774

2014

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1213-1227

2023

Link zum Volltext

Verfügbarkeit prüfen

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100431-100431, Article 100431

2023

Link zum Volltext

Verfügbarkeit prüfen

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.270-278

2013

Link zum Volltext

Verfügbarkeit prüfen

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100624-100624, Article 100624

2024

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Journal of clinical oncology, 2023-04, Vol.41 (11), p.1992-1998

2023

Link zum Volltext

Verfügbarkeit prüfen

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

Molecular cancer therapeutics, 2010-07, Vol.9 (7), p.1985-1994

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 216

Suche als RSS-Feed

Aktive Filter

ThemaMale

KollektionElectronic Journals Library - Freely accessible e-journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(216)

Publikationsform

Artikel
(215)
Texte
(1)

Sprache

Englisch
(216)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Life Sciences & Biomedicine
(65)
Oncology
(64)
Humans
(43)
Respiratory System
(33)
Lung Neoplasms - Drug Therapy
(22)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(21)
Lung Cancer
(20)
Immunotherapy
(14)
Mutation
(14)
Carcinoma, Non-Small-Cell Lung - Pathology
(12)
Lung Neoplasms - Pathology
(11)
Cancer
(10)
Chemotherapy
(10)
Cancer Research
(9)
Cancer Therapies
(9)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)
Original
(9)
Lung Neoplasms - Genetics
(8)
Nsclc
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

High efficiency vortex trapping of circulating tumor cells

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

Aktive Filter

Suchergebnisse filtern